Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Assets (2018 - 2026)

10x Genomics' Assets history spans 8 years, with the latest figure at $1.0 billion for Q4 2025.

  • On a quarterly basis, Assets rose 13.36% to $1.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 billion, a 13.36% increase, with the full-year FY2025 number at $1.0 billion, up 13.36% from a year prior.
  • Assets hit $1.0 billion in Q4 2025 for 10x Genomics, up from $1.0 billion in the prior quarter.
  • Over the last five years, Assets for TXG hit a ceiling of $1.0 billion in Q4 2025 and a floor of $903.4 million in Q1 2025.
  • Historically, Assets has averaged $977.5 million across 5 years, with a median of $984.8 million in 2023.
  • Biggest five-year swings in Assets: soared 67.74% in 2021 and later decreased 8.99% in 2024.
  • Tracing TXG's Assets over 5 years: stood at $1.0 billion in 2021, then increased by 1.0% to $1.0 billion in 2022, then dropped by 6.2% to $965.1 million in 2023, then fell by 4.82% to $918.6 million in 2024, then grew by 13.36% to $1.0 billion in 2025.
  • Business Quant data shows Assets for TXG at $1.0 billion in Q4 2025, $1.0 billion in Q3 2025, and $980.0 million in Q2 2025.